Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Concord Healthcare Group Co., Ltd. Class H ( (HK:2453) ) just unveiled an update.
Concord Healthcare Group Co., Ltd. announced that its subsidiary, Guangzhou Concord Cancer Center, completed China’s first proton therapy for choroidal malignant melanoma. This advancement provides a new eye-preserving treatment option, avoiding the traditional method of enucleation, and marks a significant milestone in the field of intraocular malignancy treatment in China.
More about Concord Healthcare Group Co., Ltd. Class H
Concord Healthcare Group Co., Ltd. operates in the healthcare industry, focusing on advanced cancer treatments. The company offers innovative therapies, such as proton therapy, through its subsidiaries like Guangzhou Concord Cancer Center, aiming to fill critical gaps in medical treatment options in China.
Average Trading Volume: 13,184,183
Technical Sentiment Signal: Sell
For detailed information about 2453 stock, go to TipRanks’ Stock Analysis page.